Literature DB >> 3190992

Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion.

R O Day1, J O Miners, D J Birkett, A Whitehead, D Naidoo, J Hayes, E Savdie.   

Abstract

1. Allopurinol usage in 50 patients of a city teaching hospital was surveyed. 2. The plasma concentrations of oxipurinol and uric acid and the urinary production of uric acid were examined. 3. The daily doses of allopurinol ranged from 50 to 1200 mg but 83% of patients were taking 300 mg daily. 4. A wide range of plasma oxipurinol concentrations was observed from 2.8 to 55.8 mg l-1 with a mean +/- s.d. of 15.2 +/- 11.7 mg l-1. 5. The population studied included a high proportion of patients with renal impairment and creatinine clearance was a significant determinant of oxipurinol concentrations (P less than 0.005). 6. There was no significant correlation between plasma urate and plasma oxipurinol concentrations and only a few plasma urates were above the upper limit of the reference range of the laboratory. 7. It was apparent that many patients were taking unnecessarily high daily doses of allopurinol and that renal status was not always considered when deciding dosage regimens of allopurinol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190992      PMCID: PMC1386564          DOI: 10.1111/j.1365-2125.1988.tb03401.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Asymptomatic hyperuricaemia.

Authors:  J T Scott
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-18

3.  Use and abuse of allopurinol.

Authors:  J S Cameron; H A Simmonds
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

4.  Plasma oxipurinol concentrations during allopurinol therapy.

Authors:  B T Emmerson; R B Gordon; M Cross; D B Thomson
Journal:  Br J Rheumatol       Date:  1987-12

5.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

6.  Inhibition of urate production by allopurinol.

Authors:  T Spector
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

7.  High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma.

Authors:  W G Kramer; S Feldman
Journal:  J Chromatogr       Date:  1979-01-01

8.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.

Authors:  J Z Singer; S L Wallace
Journal:  Arthritis Rheum       Date:  1986-01

10.  Allopurinol kinetics.

Authors:  K Hande; E Reed; B Chabner
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

View more
  15 in total

1.  Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy.

Authors:  G M Peterson; R R Boyle; H W Francis; N W Oliver; J Paterson; R J von Witt; G R Taylor
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  New uses for allopurinol.

Authors:  R O Day; D J Birkett; M Hicks; J O Miners; G G Graham; P M Brooks
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 3.  Pathophysiology, clinical presentation and treatment of gout.

Authors:  Gim Gee Teng; Raj Nair; Kenneth G Saag
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.

Authors:  Angelo L Gaffo; Kenneth G Saag
Journal:  Core Evid       Date:  2010-06-15

5.  1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.

Authors:  D J Birkett; J O Miners; R O Day
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

6.  The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.

Authors:  Daniel F B Wright; Lisa K Stamp; Tony R Merriman; Murray L Barclay; Stephen B Duffull; Nicholas H G Holford
Journal:  Eur J Clin Pharmacol       Date:  2013-03-10       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 8.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

9.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.

Authors:  S E Fowles; S K Pratt; J Laroche; W T Prince
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.